#None #Abbott #Atrial Fibrillation #Amulet 360

Abbott Introduces Amulet 360™ for Atrial Fibrillation Patients

Abbott, a leading name in global healthcare, has recently announced that its latest innovation, the Amulet 360™ Left Atrial Appendage (LAA) Occluder, has received the prestigious CE Mark. This next-generation device is poised to enhance the treatment options available to patients suffering from atrial fibrillation (AFib), particularly those at heightened risk of stroke.

The Significance of the Amulet 360™

Understanding Atrial Fibrillation

Atrial fibrillation is a common irregular heartbeat condition that can lead to serious complications, including stroke. The LAA, a small pouch connected to the heart's upper left chamber, is where blood clots tend to form in patients with AFib. Given the risks, doctors often recommend closure of the LAA as a preventive measure.

How Amulet 360™ Works

The Amulet 360™ offers a minimally invasive solution that safely seals the LAA, thus significantly reducing the need for long-term blood-thinning medications. With advancements in design and functionality, this device promises to provide doctors with better tools to tailor treatments to individual patient anatomies. The Amulet features a redesigned, softer body and smaller anchors that enhance its fit in various LAA shapes, improving closure efficacy.

Clinical Validation and Reach

Recently presented clinical trial evidence underpinned the device's CE Mark approval. The VERITAS Study, which involved 400 patients across more than 30 hospitals in the U.S., Canada, and Europe, demonstrated compelling results:

• - High Implant Success Rate: The device was successfully implanted in an impressive 99.8% of participants.
• - Safety Profile: No immediate complications such as strokes or additional surgeries were reported in the first week post-implantation.
• - Effective Closure Rates: By the 45-day mark, 93.9% of patients achieved complete LAA closure.

Dr. Xavier Freixa, a renowned interventional cardiologist from Hospital Clínic de Barcelona, remarked on the device's potential, stating, "With Amulet 360, doctors can help protect more people with AFib from stroke by confidently closing the left atrial appendage."

Future Expansion in Europe

As part of its deployment strategy, Abbott has already initiated the first European cases of Amulet 360 at prestigious locations, including Cardiovascular Clinic Bethanien in Frankfurt and Aarhus University Hospital in Denmark. The company anticipates further expanding the availability of this groundbreaking device across additional European nations in the near future.

The Broader Impact on Healthcare

The Amulet 360™ device is another significant addition to Abbott's established portfolio of technologies aimed at addressing cardiac arrhythmias. This marks Abbott's fourth major electrophysiology approval in just over a year, highlighting its ongoing commitment to enhancing outcomes for patients confronted with heart conditions.

Conclusion

In summary, Abbott's Amulet 360™ Left Atrial Appendage Occluder stands as a testament to innovation in the medical device industry. By merging cutting-edge technology with practical clinical application, this device aims to lower stroke risks and improve the quality of life for a countless number of AFib patients across Europe and beyond. With the promise of effective stroke prevention, Amulet 360™ is set to redefine treatment protocols for patients at risk of stroke due to AFib.

For more details on Abbott's offerings, visit www.abbott.com.